Board approves three investment plans Spike Pharmaceuticals expands again
Release time:
2020-08-14
News from our newspaper 8# April 3 , the group company held the fifth meeting of the 10th board of directors, deliberated and passed three proposals on the capital increase of Shanghai Beika by Jianfeng Pharmaceutical, the acquisition of Anhui Zhongwang Pharmaceutical Company by subsidiary Shanghai Beika, and the annual production of 20 .8 billion solid preparations in Jinxi Production Base of Jianfeng Pharmaceutical.
The three investment plans approved by the board of directors this time are important measures to further strengthen the company's pharmaceutical business segment in accordance with the company's strategic policy of "cooperating and innovating to strengthen the main business, standardizing science and seeking development. Among them, Jianfeng Pharmaceutical Co., Ltd. invested ,000 yuan to increase the capital of Shanghai North Card. After the capital increase is completed, Jianfeng Pharmaceutical Co., Ltd. will account for 61.48% of Shanghai North Card. Shanghai North Card will invest 2062 yuan to acquire Anhui Zhongwang 100% equity.
In 1 this year, Jianfeng Pharmaceutical signed an agreement with relevant parties to invest in Shanghai Beika by way of equity acquisition and capital increase, and completed the investment in 5 . Shanghai Beika and its subsidiary Anhui Xinbeika Company have become the controlling subsidiary of Jianfeng Pharmaceutical. Anhui Zhongwang, which Shanghai Beika acquired this time, is also located in Dongzhi Xiangyu Chemical Industrial Park, Chizhou City, Anhui Province. It is a pharmaceutical intermediate manufacturing enterprise integrating R & D, production and sales, focusing on the R & D, production and sales of characteristic medicines, intermediates, new materials and other fine chemicals. Anhui Zhongwang's main products are oxyfluorocarbons, oxyfluorocarbons, levooxyfluorocarbons, and levooxyfluorocarbons, which have passed on-site audits by well-known domestic pharmaceutical companies. L-fluorocycloester passed an on-site audit of a pharmaceutical company in India. 2017 12 accepted the on-site audit of oxyfluorocarboxylic acid process verification by U.S. pharmaceutical companies, and Zhongwang has been registered as a supplier of oxyfluorocarboxylic acid starting materials in U.S. document DMF . After the completion of the acquisition, the company will make use of Anhui Zhongwang's factory buildings and construction land to plan the construction of pharmaceutical intermediates and API projects, so as to provide a strong guarantee for Jianfeng Pharmaceutical to establish a chemical API base.
At the same time, Jianfeng Pharmaceutical will also invest 50146 yuan to set up a new factory on the north side of the existing factory area of Jianfeng Pharmaceutical in Jinxi District of Jinhua Economic Development Zone to build a preparation manufacturing platform that meets the requirements of GMP in Europe and America. (remaining fruit)
More information
The company's vocational skill level independently identifies two new occupations
A few days ago, after the examination and approval of the Jinhua Municipal Bureau of Human Resources and Social Security, and reported to the Provincial Department of Human Resources and Social Security for examination and filing, Jianfeng Group's independent identification level of vocational skills was based on last year. Two new occupations (types of work) are chemical inspectors and organic synthesis workers.
2022
05-20
On May 12, Cai Xiaochun, deputy secretary of the Party group of Zhejiang Federation of industry and commerce, and his party visited Jianfeng group for investigation, visited Jinxi factory area of Jianfeng pharmaceutical factory and Jinxi internationalization project site, and had a discussion with Jiang Xiaomeng, chairman of the group company, Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company.
2022
05-20
On the afternoon of April 6, Jiang Xiaomeng, chairman of the group company, was invited to participate in the Jinhua News Client Financial Media Interview column "Night Talk of the Two Sessions", as a representative of the Jinhua Municipal People's Congress, to talk about suggestions for the future development of Jinhua enterprises. As the chairman of the Jinhua City Federation of Industry and Commerce, Jiang Xiaomeng has a personal experience of various problems encountered in the development of Jinhua enterprises. After careful investigation and full preparation, he put forward two proposals on strengthening the empowerment and allocation of production factors and further enhancing the market competitiveness of enterprises in our city and further promoting the compliance construction of private enterprises in our city and reducing the risk of enterprise operation. In the "two sessions night talk" interview, he put forward his own views on these two topics.
2022
04-12
Group Companies Commend 2021 Advanced
On the morning of January 26, the group company held the 2021 annual summary commendation meeting to review the work of the previous year, make arrangements for the work of 2022, sign the 2022 economic responsibility system with various professional companies and directly affiliated enterprises, and solemnly commend the 2021 advanced collectives and individuals.
2022
02-08
Group Company Convenes Workers' Representative and Trade Union Member Representative Conference
The group company held a representative meeting of staff representatives and trade union members, elected members of the eighth trade union committee and members of various special committees, and Shi Fu was elected chairman of the eighth trade union of the group trade union.
2022
02-08
The group company held an annual safety and environmental protection work conference to comprehensively summarize and review the safety and environmental protection work in 2021, make arrangements for the safety and environmental protection work in 2022, and sign the safety and environmental protection work responsibility system.
2022
02-08